INS and Hypoglycemia: Vilsboll et al. (2019) found that combining dapagliflozin and saxagliptin significantly reduced body weight in insulin-naive T2DM patients while maintaining similar glycemic control and a lower hypoglycemia risk compared to basal insulin [22].